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ABSTRACT
Aim: To assess oral signs, symptoms and oral lesions (OL) type and prevalence, in diabetic patients with end stage re-
nal disease (ESRD DM), and compare them with analogous findings in a non-ESRD DM group; analyze the possible 
association between oral manifestations, as well as with relevant laboratory findings.
Research design. Two adult groups were studied: Group A: ESRD DM on dialysis, and group B: non-ESRD DM (serum 
creatinine <2.0 mg/dl). Known DM evolution time, dialysis treatment type and duration, and laboratory results were 
recorded. An oral exam was performed, searching for signs, symptoms and ESRD-associated OL.  Associations were 
analyzed using Chi square, Fisher’s exact test, and odds ratios (OR) with 95% confidence intervals. Ages, time on dialysis, 
and laboratory results were compared with Student’s t test.
Results: 229 individuals were examined, group A 99, and group B 130 pts. Signs and symptoms prevalence was higher 
in group A: 77.8% vs. 57.6%, (P<0.001), uremic breath (48.5%), unpleasant taste (45.5%) and xerostomia (44.4%) being 
the most frequent ones. OL were also more prevalent in group A; 65.6% vs. 36.9% (P<0.001). The most frequent OL 
were dry, fissured lips (28.3%), saburral tongue (18.2%) and candidiasis (17.2%). No difference was found in candidiasis 
prevalence between groups. Candidiasis was found associated to xerostomia (P<0.05) and smooth tongue (P<0.05) only 
in group A.
Conclusions. ESRD DM patients had a significantly higher prevalence of signs, symptoms and OLs, as compared to 
non-ESRD DM pts. The high prevalence of uremic fetor, xerostomia, saburral tongue and candidiasis in group A, could 
be tried as warning signs on the possibility of non diagnosed advanced renal disease in other diabetic patients.
Key words: End stage renal disease, diabetes, uremic fetor, xerostomia, saburral tongue.
RESUMEN
Objetivos. Conocer el tipo y frecuencia de signos, síntomas y lesiones bucales (LB) en pacientes diabéticos (DM) con 
insuficiencia renal crónica (IRCT), y compararlos con un grupo de DM sin IRCT. Investigar la posible asociación de 
las manifestaciones bucales entre sí, y con resultados de laboratorio relevantes.
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INTRODUCTION
End stage renal disease (ESRD) is the final syndrome for 
several primary renal diseases, and systemic diseases with 
renal involvement, causing kidney function loss. ESRD 
manifestations involve virtually every system, in a clinical 
condition known as uremic syndrome, characterized by 
a profound alteration of water, electrolyte, and acid-base 
homeostasis, as well as retention of uremic toxins norma-
lly eliminated through urine, especially protein catabolism 
nitrogen waste products (1). The condition is incompatible 
with life, unless the patient starts chronic dialysis treatment 
or kidney transplantation.
ESRD incidence and prevalence are increasing, as shown 
in consecutive United States Renal Data System (USRDS) 
annual data reports. All age groups are affected, but ESRD 
is predominantly an adult disease. ESRD cause was diabetes 
in 44.8% of incident USA cases in 2003 (2). In that same 
report, chronic dialysis patients prevalence was 1,496 per 
million, and median age at dialysis start increased from 52.8 
years in 1980, to 62.7 years in 2003, reflecting improved 
kidney disease medical care (2).
An ESRD prevalence study on Instituto Mexicano del 
Seguro Social (IMSS)-affiliated adults (>18 yr), estimated 
1.142 persons with creatinine clearance levels <15 ml/min 
per million adult affiliates (3). That level of renal function 
damage does already, or will soon, need dialysis treatment 
(4). Another study on IMSS affiliates found diabetes mellitus 
as the cause of ESRD in 41.1% of incident cases (5). ESRD 
mortality is increasing in Mexico; being now 9th cause for 
women and 10th for men (6).
Diabetes mellitus is an important risk factor for ESRD. In 
Mexico, Amato et al. (3) reported a 10.9% DM prevalence 
in 18 yr and older individuals, and found 48.6% of affected 
subjects unaware. Diabetic patients are at risk for acute and 
chronic complications, including those on the oral cavity (7) 
such as xerostomia, glossodynia, bacterial, viral, and fungal 
infections, and periodontal disease (7-9). A 36.6% to 67% 
association frequency has been reported between diabetes 
and oral candidiasis (10).
An up to 90% prevalence has been reported in renal disease 
patients, either on dialysis or with a kidney transplant, for at 
least one of more than 30 different signs, symptoms, or oral 
lesions associated in medical literature to uremic syndrome 
and kidney transplant, including xerostomia, uremic fetor, 
pale mucosa, uremic stomatitis and candidiasis (11,13).
The aim of this study was to assess signs, symptoms, and 
oral lesions (OLs) type and prevalence, in a group of ESRD 
DM patients on dialysis treatment, and compare them with 
a group of non-ESRD diabetic patients, exploring possible 
associations among oral lesions, and between OLs and 
relevant clinical laboratory results. 
MATERIAL AND METHODS
Observational, comparative, transversal study, performed 
in two groups of patients: Group A, ESRD DM, formed 
by consecutive diabetic patients 18 yr and older, both sexes, 
with diabetic nephropathy – induced ESRD, attending the 
outpatient nephrology clinic or the  peritoneal or hemo-
dialysis units for dialysis treatment follow-up, and Group 
B, non-ESRD DM, formed by consecutive diabetic patients 
18 yr and older, both sexes, attending outpatient family me-
dicine clinic for diabetes mellitus follow-up. Patients with a 
serum creatinine ≥ 2.0 mg/dl were excluded. The study was 
carried out at an IMSS general hospital at San Luis Potosi. 
Demographical data, time from DM diagnosis, dialysis 
treatment type and duration, clinical laboratory results for 
blood hemoglobin, fasting glycemia, urea, creatinine and 
albumin were collected. Hb A1C results were not available. 
An informed consent was obtained from each patient to 
participate in the survey.
An examination was performed of all oral mucosa areas, re-
cording ESRD-associated signs, symptoms, and OL absence 
or presence. Signs and symptoms identification was objecti-
vely searched for, and/or reported by patients. A diagnosis 
of xerostomia was made when a dry or sticky mucosa was 
found, and when the patient reported a dry mouth; saliva 
flow was not measured. Uremic fetor was identified when 
the patient had a urine-odor breath.
Diseño del estudio. Fueron dos grupos de adultos: grupo A: DM con IRCT y diálisis, y grupo B: DM sin IRCT (con 
creatinina sérica <2.0 mg/dl). Se registró tiempo de evolución conocida de la DM, tipo y duración del tratamiento dia-
lítico y resultados de laboratorio. Se realizó un examen bucal registrando signos, síntomas y LB asociadas a IRCT. Las 
asociaciones se investigaron con χ2, prueba exacta de Fisher y razón de momios (RM) con límites confianza de 95%. 
Las edades, el tiempo en diálisis y los resultados de laboratorio se compararon con prueba de T de Student.
Resultados.  Fueron 229 sujetos; grupo A 99 y grupo B 130. La frecuencia de signos, síntomas fue mayor en el grupo A: 
77.8 % vs. 57.6%, (P <0.001); los más frecuentes fueron aliento urémico 48.5%, sabor desagradable 45.5% y xerostomía 
44.4%. Las LB también fueron más frecuentes en el grupo A; 65.6% vs. 36.9%, (P<0.001). Las más frecuentes fueron 
labios secos y fisurados 28.3%, lengua saburral 18.2% y candidosis 17.2%. No se encontró diferencia en la prevalencia 
de candidosis entre los dos grupos. La candidosis se asoció con xerostomía (P<0.05) y con dorso de lengua liso (P<0.05) 
solo en el grupo A.
Conclusiones. Los diabéticos con IRCT presentaron un número significativamente mayor de signos, síntomas y LB que los 
diabéticos sin IRCT. La elevada frecuencia de aliento urémico, xerostomía, lengua saburral y candidosis en el grupo A, po-
drían probarse como señales de alerta sobre la posibilidad de enfermedad renal avanzada en otros pacientes diabéticos.
Palabras clave:  Insuficiencia renal crónica, diabetes, aliento urémico, xerostomía, lengua saburral.
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OL diagnosis used acknowledged clinical diagnosis criteria 
for ESRD-associated oral manifestations (11-13), and oral 
candidiasis was diagnosed by Holmstrup criteria (14).
Uremic stomatitis: irregular-shaped mucosal erythema, 
covered by grayish pseudomembranes on the lateral borders 
or inferior aspect of the tongue, occasionally symptomatic 
(11, 12).
Saburral tongue (ST): Yellowish-white plaque on tongue 
dorsum, which could not be scraped-off  by a blunt ins-
trument. Slightly elongated filiform papillae and bacterial 
accumulation were found (15). A periodic acid-Schiff (PAS)-
stained cytological smear ruled out candidiasis.
Erythematous candidiasis: Dorsal tongue or vestibular 
mucosal rounded or ovoid-shaped, depapillated, red area. 
Sub plaque candidiasis: Red area on hard palate, comprising 
the total or partial prosthesis area, sometimes with a punc-
tated or small papule-filled appearance.  Candidiasis was 
confirmed by gemmating hyphae, found in a PAS-stained 
cytological smear (14).
Statistical analysis
Descriptive statistics were calculated: frequencies, percenta-
ges, means and standard deviations. Inter- and intra-group 
variable associations were analyzed with Chi square and 
Fisher’s exact tests, where applicable, and by odds ratio 
(OR) with 95% confidence limits (95% CL). Age, diabetes, 
and dialysis duration were compared with Student’s t test 
for unpaired samples with homogenous variances. A P<0.05 
value was considered statistically significant.
RESULTS
A total of 229 individuals were studied. Group A, 37 men 
and 62 women, ages 57.9 ± 11.6 (17 to 83) years, and group 
B, 43 men and 87 women, ages 58.8 ± 11.6 (18 to 77) years 
(P = NS). Median known DM evolution time: group A, 240 
(24 to 408), and group B, 84 (2 to 180) months (P <0.001). 
Median dialysis treatment time: group A, 8 (1 to 88) mon-
ths. Table 1 shows clinical laboratory results, revealing, as 
expected, significant differences in urea, creatinine, and Hb 
values, corresponding to ESRD and Non-ESRD diagnosis 
for both groups.
Oral symptoms and signs: Table 2 compares their prevalence 
in groups A and B, showing odds ratios with 95% CL; Group 
A had a 77.8% and group B a 57.6% prevalence for at least 
one symptom or sign (P <0.001).
Oral lesions: 97 lesions were found in 65 group A patients; 
41 cases had one lesion, 17 cases two, 6 cases three, and 1 
patient had four simultaneous lesions; 67 lesions were identi-
fied in 48 group B patients; 33 individuals had one lesion, 12 
had two, 2 had three lesions, and 1 patient had four simulta-
neous lesions. Total OL prevalence was greater in group A, 
65.6% vs. 36.9% (P<0.001). Table 3 compares OL prevalence 
in both groups showing odds ratios and 95% CL. There 
was no difference in candidiasis prevalence. Table 4 shows 
identified intra-group associations between symptoms, signs, 






DM, Group B 
P
n 99 130  
Hemoglobin
(g/dl)




 175 ± 110 176 ± 91 NS 
Urea (mg/dl) 122 ± 54 38 ± 48 <0.001 
Creatinine 
(mg/dl)
 8.1 ± 3.2 1.0 ± 0.4 <0.001 




DM, Group B 




fetor 48 48.5 0 0.0 NA NA 
Unpleasant 
taste 45 45.5 35 26.9 <0.01 
2.3
(1.3 to 3.9) 
Xerostomia 44 44.4 47 36.2 NS 
1.4
(0.8 to 2.4) 
Pale 
mucosa 40 40.4 16 12.3 <0.001 
4.8
(2.5 to 9.3) 
Yellowish 
mucosa 14 14.1 6 4.6 <0.01 
3.4
(1.3 to 9.2) 
Burning
tongue 13 13.1 13 10.0 NS 
1.4




77 77.8 75 57.6 <0.001 
2.6
(1.4 to 4.6) 
Table 1. Clinical laboratory studies, ESRD and Non-ESRD diabetic 
patients.
Table 2. Oral symptoms and signs in ESRD and Non-ESRD diabetic 
patients.
OR= Odds ratio, 95% CL= 95% confidence limits, NA = not applicable
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No association was found between smooth tongue and 
serum albumin or hemoglobin, or between the presence of 
up to eight signs, symptoms, or OL, and a serum albumin 
below 3.0 g/dl. No association was found between xerosto-
mia and fasting glycemia or saburral tongue. Microscopic 
examination of saburral tongue smears revealed abundant 
bacteria. No cultures were made allowing identification.
DISCUSSION
Symptoms, signs and OL prevalence were significantly 
higher in ESRD DM patients as compared to Non-ESRD 
DM. Almost 78% of group A patients had at least one 
symptom or sign, the most prevalent ones being uremic 
fetor and unpleasant taste, which were found associated. 
Uremic fetor was also associated to a yellowish discolora-
ESRD DM,   
 Group A 
Non-ESRD DM,   
 Group B 
Oral lesions Cases % Cases % P
OR
(CL 95 %) 
Dry, fissured 
lips 28 28.3 20 15.4 <0.05 
     2.2  
(1.1 to 4.1) 
Saburral 
tongue 18 18.2 4 3.0 <0.001 
    7.0   
(2.3 to 21.4) 
Candidiasis 17* 17.2 29** 22.3 NS    0.7  (0.4 to 1.4) 
    
Erythematous 11 11.1 20 15.4 NS 
   0.7  
(0.3 to 1.5) 
    Subplaque 8 8.0 14 10.8 NS    0.7  (0.3 to 1.8) 
Petechiae or 
ecchymoses 15 15.1 1 0.8 <0.001 
  23.0   
(3.0 to 178) 
Smooth
tongue 13 13.1 5 3.8 <0.01 
   3.8  
(1.3 to 11.0) 
Ulcerative 
stomatitis 2 2.0 0 0 NA NA 
Herpes 
simples 2 2.0 2 1.5 NS 
1.3     
(0.2 to  9.5) 
Angular
cheilitis  2 2.0 6 4.6 NS 
0.4     
(0.1 to 2.2) 
Total oral 
lesions  65 65.6 48 36.9 <0.001 
3.3      
(1.9 to 5.6) 
Table 3. Oral lesions in ESRD and Non-ESRD diabetic patients. 
OR=Odds ratio, 95% CL= 95% confidence limits, NA= not applicable, NS = not significant
* Two patients presented simultaneous erythematous and sub-plaque candidiasis
** Five patients presented simultaneous erythematous and sub-plaque candidiasis
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tion in the mucosa, and to xerostomia. Uremic fetor occurs 
as a result of a high urea concentration in saliva, and its 
ensuing conversion to ammonia (16). additional possible 
causes are increased phosphate and protein concentrations, 
and changes in saliva pH, which might explain a metallic 
or unpleasant taste (1, 12, 17). The 48.5% uremic fetor and 
45.5% unpleasant taste found in group A is similar to that 
reported by Kao et al. (50.0%) (17) and Kho et al. (34.1%) 
(18) in ESRD hemodialysis patients. Chuang et al. (19) in-
formed a higher prevalence of severe symptoms in diabetics, 
as compared to non-diabetics in a study of ESRD patients. 
The higher prevalence of  oral manifestations in ESRD 
DM could be either a worsening of preexisting alterations, 
caused by longer evolution of DM in group A, or be caused 
by uremia.
Dry mouth in ESRD patients is a multifactorial phenome-
non (17): water restriction, low saliva flow (17, 18, 20, 21), 
minor salivary glands parenchymal fibrosis and atrophy (21), 
mouth breathing and medication use (12) being identified 
factors. The 44.4% found xerostomia prevalence in group 
A agrees with 32.9% to 68% figures reported in other stu-
dies of dialysis patients (17, 18, 21). Xerostomia is also a 
frequent symptom in the non-ESRD DM patient (7,8), and 
its prevalence in group B was 36.2%. Minor salivary glands 
involvement by microvascular disease and neuropathy play 
an important role in this symptom (7,8,10). Xerostomia in 
the ESRD DM patient is a risk factor for candidiasis, dental 
caries, periodontal disease, and bacterial infections, because 
of the lost protective action  of saliva (17,20).  Xerostomia 
is also associated to taste loss (21). A higher prevalence of 
oral manifestations (19) and gingival calculi (16, 18) has 
been described in ESRD patients with xerostomia. Chuang 
Group 
A
Symptom, sign or 
lesion 1 
Symptom, sign 
or lesion 2 
Test P OR (CL 95 %) 
 Uremic fetor Xerostomia � 2 <0.05 2.6  (1.1 to 5.8) 
 Uremic fetor Unpleasant taste � 2 <0.001 14.0 (5.3 a 37.0) 
Uremic fetor Yellowishmucosa �
2 <0.01 8.2 (1.7 to 38.8) 
 Xerostomia Unpleasant taste � 2 <0.05 2.3 (1.0 to 5.2) 
Xerostomia Erythematous candidiasis �
2 <0.05 3.8  (1.0 to 15.5) 





e.t. <0.01 10.0 (1.2 to 81.5) 
Smooth tongue Erythematous candidiasis 
Fisher’s
e.t. <0.05 5.0 (1.2 to 20.5) 




2 <0.05 3.4 (1.1 to 10.7) 





e.t. 0.07 4.7 (0.8 to 26.8) 
Group 
B Xerostomia Unpleasant taste �
2 <0.001 8.3 (3.5 to 19.9) 
Table 4. Intra-group associations found between, symptoms, signs, oral lesions and clinical laboratory 
data in ESRD and Non-ESRD diabetic patients.
OR = Odds ratio, 95 % CL= 95% confidence limits, Fisher’s e.t = Fisher’s exact test.
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et al. (19) reported a possible association between dry 
mouth and poor glycemic control in hemodialysis patients. 
Glycemic control was poor for both of our study groups, 
which probably was a factor in the high prevalence of the 
symptom.
Mucosa pallor is explained mainly by anemia, a multifactorial 
complication in the ESRD patient caused by erythropoietin 
and folic acid deficiencies, inhibited erythropoiesis, shorte-
ned erythrocyte life span, hemolysis and hemodialysis com-
plications, among other (1,11,12). Pale mucosa prevalence 
was significantly higher in group A. The χ2  test could not, 
however, find an association to blood Hb, perhaps because 
normal Hb values were missing in group A patients. Pale 
mucosa has also been associated to malnutrition (11), a re-
portedly frequent finding (82%) in Mexican dialysis patients, 
especially diabetic women (22). We were not able to find an 
association between pale or yellowish mucosa and a serum 
albumin <3.0 g/dl. The yellowish mucosa discoloration is 
caused by urocromo pigments (1,11, 12). 
Our findings are in agreement to previous reports of ESRD 
predisposing to oral lesions. The most frequent OL were 
dry- fissured lips, saburral tongue, and candidiasis. Saburral 
tongue is an asymptomatic entity. Its prevalence in group A 
was 18.2%, no association being found to other oral mani-
festations. Reported prevalences are 12.2% to 47.1% (17-19). 
Chuang et al. (19) found 47.1% in non-diabetic and 39.5% 
in diabetic Chinese hemodialysis patients. Saburral tongue 
is caused by retention of desquamated epithelial cells and 
dead leucocytes on filiform papillae (15), and by volatile 
sulfurous compounds produced by anaerobic bacteria on 
the tongue surface, almost always the same as those found in 
the subgingival plaque (23). Saburral tongue has also been 
described as filiform papillae enlargement, with bacteria 
accumulation due to factors such as a water-restricted diet, 
low saliva flow, poor oral hygiene, and even the emotional 
condition of the dialysis patient (15, 24). It has also been 
reported in transplanted patients: 22.2% in kidney- and 
28.3% in liver- transplant patients (25, 26).
The causes of the immunocompromised condition of the 
dialysis patient are uremia, malnutrition, dysfunctional 
celular immunity. Immunocompromise increases the risk 
for opportunistic Candida sp infections. (12). Other known 
risk factors for candidiasis are xerostomia, low saliva flow, 
total dental prosthesis, poor oral hygiene, age, diabetes (13, 
27). In agreement to other reports (18, 19), candidiasis was 
found associated to xerostomia in group A, and an almost 
significant association was also found to a low serum albu-
min, odds ratio 4.7, 95% CL 0.8 to 27. The association of 
candidiasis to pale mucosa and smooth tongue could suggest 
malnutrition predisposing Candida infection. Erythema-
tous candidiasis was the most common type, in most cases 
occurring on tongue dorsum. The similar prevalence of 
candidiasis found in groups A and B could mean a stronger 
association of candidiasis to diabetic, as compared to ESRD 
condition. Poor glycemic control in both groups could 
also be a risk factor for candidiasis. We found candidiasis 
associated to a fasting glycemia above 200 mg/dl in group 
A, but not in group B. On the other hand, dental prosthe-
sis-associated candidiasis was more prevalent in group B, 
because edentulous non ESRD DM patients wore a total 
prosthesis more frequently than edentulous ESRD DM pa-
tients. Reported prevalences of oral Candida sp infection in 
dialysis patients are 5.7 to 37% (28,24), differences probably 
being caused by diagnostic criteria discrepancy. Klassen and 
Krasko (29), for instance, reported a 1% central rhomboid 
glossitis and 12% erythematous patches prevalences in 
dialysis patients, both probably equivalent to candidiasis. 
In that same study (29), angular cheilitis was reported in 
4% patients. Angular cheilitis has been found associated to 
Candida sp. infections and anemia (14,27). Its prevalence in 
group A was 2%. The impact of oral candidosis diagnosis 
and treatment is to improve oral symptoms and lowering 
the risk for dissemination to other organs.
Platelet aggregation is altered in uremia (1, 30), which, added 
to heparin and other anticoagulants used in hemodialysis, 
predisposes to ecchymosis, petechiae and hemorrhages in the 
oral cavity (24,30). We found 15.2% cases with ecchymosis 
and/or petechiae in group A, vs. 0.8% in group B (P<0001). 
Kho et al. (18) found petechiae and/or ecchymosis in 12.2% 
of their dialysis patients, and figures as high as 23.3% have 
been reported in diabetic and non diabetic ESRD patients 
(17, 19). These lesions were found on oral examination, and 
had modest clinical relevance.
Oral mucosa ulcerations are yet another class of OLs in 
dialysis patients, with reported prevalences of 1.2 to 10% 
(17, 19, 28, 29). Uremic stomatitis, now an uncommon 
OL because of usually earlier dialysis therapy for ESRD 
patients, is a localized or generalized burning oral mucosa 
erythema, with erythematous areas covered by a grayish 
pseudomembranous exudate leaving, on removal, an intact 
(type I) or ulcerated (type II) mucosa (12, 13, 31). It has also 
been described as white plaques on vestibular mucosa and 
tongue dorsum or belly (31, 32), called hyperparakeratosic 
uremic stomatitis, often coexisting with Candidiasis. Its 
etiology is unknown. It has been considered the reaction 
to a tissular irritant (13, 32) possibly ammonia compounds 
derived from urea hydrolysis by salivary urease, whenever 
saliva urea concentration exceeds 180 mg/dl (32). We found 
two cases, just starting dialysis therapy, with OL matching 
uremic stomatitis description. Uremia control is the main 
therapy; 10% hydrogen peroxide gargles (1:1 in water) q.i.d. 
assist on lesion healing (32).
CONCLUSIONS
ESRD DM patients had a significantly higher prevalence 
of signs, symptoms and oral lesions, as compared to non-
ESRD DM patients. This observation agrees with previous 
reports of ESRD predisposing to oral manifestations in the 
diabetic patient. Even if  an association might be expected 
between oral manifestations type or number and nutritio-
nal status in the diabetic dialysis patient, we were not able 
to find an association between several oral manifestations 
and serum albumin, a sensible –but non specific- marker 
of nutritional status in the diabetic dialysis patient. Oral 
Oral Medicine and Pathology                                                                                                                                                                                                              Med Oral Patol Oral Cir Bucal 2006;11:E467-73.                                                           Oral Medicine and Pathology                                                                               �  Med Oral Patol Oral Cir Bucal 2006;11:E467-73.
E473
© Medicina Oral S.L. Email: medicina@medicinaoral.com
manifestations were, moreover, barely symptomatic when 
present, or were probably less of a trouble for the patient 
as compared to other manifestations of ESRD. Those fre-
quently found conditions of uremic fetor, unpleasant taste, 
xerostomia, pale or yellowish mucosa, burning tongue, dry- 
fissured lips, candidiasis, saburral- or smooth tongue in our 
study group, could be tried as warning signs for undiagnosed 
kidney disease in other diabetic patients. OL diagnosis and 
treatment will contribute to improve the quality of life of 
the difficult ESRD DM patient.
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